Ignite Creation Date:
2025-12-24 @ 10:03 PM
Ignite Modification Date:
2025-12-28 @ 11:03 PM
Study NCT ID:
NCT01682135
Status:
COMPLETED
Last Update Posted:
2016-08-26
First Post:
2012-09-06
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study in Participants With Advanced Solid Tumors
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2016-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| I4T-CR-JVBU | OTHER | Eli Lilly and Company | View |